← FDA DRUG APPROVALS

FDA ANDA · ANDA076455

VELIVET TRIPHASIC REGIMEN

desogestrel and ethinyl estradiol

Sponsor: DURAMED PHARMS BARR

APPLICATION
ANDA076455
TYPE
ANDA
ORIGINAL APPROVAL
2004-02-24
LATEST ACTION
2011-07-14
ROUTE
Oral, ORAL-28
DOSAGE FORM
Tablet, TABLET
MARKETING STATUS
Prescription

Products

DESOGESTREL; ETHINYLPrescription
DESOGESTREL 0.15MG/0.025MG, ETHINYL ESTRADIOL · Tablet · Oral
VELIVETPrescription
DESOGESTREL 0.1MG,0.125MG,0.15MG, ETHINYL ESTRADIOL 0.025MG,0.025MG,0.025MG · TABLET · ORAL-28
DESOGESTREL; ETHINYLPrescription
DESOGESTREL 0.125MG/0.025MG, ETHINYL ESTRADIOL · Tablet · Oral

Approval history

2011-07-14Labeling · Supplement 11AP
2004-02-24OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →